Pharmaceutical Corruption Media Articles
Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.
For further exploration, delve into our comprehensive Health and Food Corruption Information Center.
Prices for a cancer drug called lomustine have skyrocketed nearly 1,400 percent since 2013, putting a potentially life-saving treatment out of reach for patients suffering from brain tumors and Hodgkin's lymphoma. Though the 40-year-old medication is no longer protected by patents, no generic version is available. According to the Wall Street Journal, lomustine was sold by Bristol-Myers Squib for years under the brand name CeeNU at a price of about $50 a capsule for the highest dose. The drugmaker sold lomustine in 2013 to a little-known Miami startup called NextSource, which proceeded to hike lomustine's price nine times since. It now charges about $768 per pill for the medication. According to an analysis done for the Journal ... NextSource this year raised prices for the drug, which it rebranded as Gleostine, by 12 percent in November following a 20 percent increase in August. Soaring prices for cancer drugs are a concern for both patients and doctors because financial pressures can lead to delays in seeking treatment that can easily surpass six figures per year. A study published earlier this year in the Journal of Clinical Oncology found prices for 24 patented injectible Medicare Part B drugs rose an average of 18 percent annually over the past eight years on an inflation-adjusted basis. Prices continued to rise even when generic versions of the drug became available.
Note: For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.
Television advertisements for prescription drugs ... have been running for 20 years. [Yet] it is not your imagination if you think you are seeing more of them these days. Lots more. 771,368 such ads were shown in 2016 ... an increase of almost 65 percent over 2012. TV ad spending by pharmaceutical companies has more than doubled in the past four years, making it the second-fastest-growing category on television during that time, Jon Swallen, Kantars chief research officer, said. The ads ... have turned to more serious ailments in the last few years. And when the ads come on, [the] audience is also listening intently to all that can befall them if they take a certain drug. An unexpected side effect of ad agency compliance with the drug administrations regulation, it turns out, is enhanced credibility. Its counterintuitive, but everything in our research suggests that hearing about the risks increases consumers belief in the advertising, said Jeff Rothstein, the chief executive officer of Cult Health, an ad agency that specializes in health care.
Note: 25 years ago drug advertising was illegal, as it was believed drugs should sell themselves on their own merits. Now Big Pharma is raking in profits hand over fist by inundating us with fear-based advertising. For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.
After months of deliberation and investigation, the WHO has concluded that cannabidiol (CBD) is a useful treatment for epilepsy and palliative care, and does not carry any addiction risks. The organization is set to run a fuller review of cannabis next year. The report ... also recommended imposing the strong restrictions available on fentanyl, a synthetic opioid which has killed thousands of people in Americas drug addiction epidemic. There is increased interest from Member States in the use of cannabis for medical indications including for palliative care, the report said. Responding to that interest and increase in use, WHO has in recent years gathered more robust scientific evidence on therapeutic use and side effects of cannabis and cannabis components. In conclusion, the authors wrote: Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions. They added that current information does not justify scheduling of cannabidiol, and declared that taking medical marijuana will not lead to addiction to THC, the psychoactive property of cannabis that induces a high.
Note: More people are arrested in the US for marijuana use than for all violent crimes combined and the US federal government continues to regard non-psychoactive CBD as a dangerous drug. The UK government recently announced it will regulate CBD as medicine. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.
For decades, Don Anderson of Seattle has been taking the same drug to help control the temporary bouts of immobility and muscle weakness caused by a rare and frightening genetic illness called periodic paralysis. The drug Anderson has been taking all these years was originally approved in 1958 and used primarily to treat the eye disease glaucoma under the brand name Daranide. The price has been on a roller coaster in recent years zooming from a list price of $50 for a bottle of 100 pills in the early 2000s up to $13,650 in 2015, then plummeting back down to free, before skyrocketing back up to $15,001 after a new company, Strongbridge Biopharma, acquired the drug and relaunched it this spring. The zigzagging trajectory of the price of Daranide, now known as Keveyis, shows just how much freedom drug companies have in pricing therapies and what a big business opportunity selling extremely-rare-disease drugs has become. In 2016, after The Washington Post asked questions about the high price of the drug, Sun Pharmaceutical said it would give the drug away free. Late last year, Sun agreed to sell Keveyis to a biotech company, Strongbridge Biopharma. In April, Strongbridge relaunched the drug. In August, it jacked the list price ... to $15,001 for a bottle of 100 pills. In a PowerPoint presentation for investors, Strongbridge Biopharma estimated that the annual price of treatment for the drug, Keveyis, would range from $109,500 to $219,000.
Note: For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
The World Health Organization said on Monday it hoped to conduct a full review by the end of the year of a dengue vaccine that was suspended last week in the Philippines. On Friday, the department of health halted its dengue immunization program after the manufacturer, French drug company Sanofi Pasteur, announced the vaccine, [commonly known as Dengvaxia], must be strictly limited due to evidence it can worsen dengue in people not previously exposed to the infection. The government of Brazil, where dengue is common, confirmed it already had recommended restricted use of the vaccine. Amid mounting public concern, Sanofi explained its "new findings" at a news conference in Manila on Monday but did not say why action was not taken after a WHO report in mid-2016 that identified the risk the company was now flagging. Nearly 734,000 children ... in the Philippines have received one dose of the vaccine as part of a programme that cost 3.5 billion pesos (more than $80 million Cdn). The Philippines Department of Justice on Monday ordered the National Bureau of Investigation to look into "the alleged danger to public health ... and if evidence so warrants, to file appropriate charges." There was no indication that Philippines health officials knew of any risks. However, the WHO said in a July 2016 research paper that "vaccination may be ineffective or may theoretically even increase the future risk" of severe dengue illness in people who hadn't been exposed to it prior to their first vaccination.
Note: Read more about this and about the way vaccines dangers are being covered up on this webpage. For more along these lines, see concise summaries of deeply revealing vaccine controversy news articles from reliable major media sources.
The Philippines ordered an investigation on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by French drug company Sanofi that it could worsen the disease in some cases. The World Health Organization said it hoped to conduct a full review by year-end of data on the vaccine, commercially known as Dengvaxia. In the meantime, the WHO recommended that it only be used in people who had a prior infection with dengue. The government of Brazil, where dengue is a significant health challenge, confirmed it already had recommended restricted use of the vaccine but had not suspended it entirely. Amid mounting public concern, Sanofi explained its "new findings" at a news conference in Manila but did not say why action was not taken after a WHO report in mid-2016 that identified the risk it was now flagging. A non-governmental organization (NGO) said it had received information that three children who were vaccinated with Dengvaxia in the Philippines had died and a senator said he was aware of two cases. Last week, the Philippines Department of Health halted the use of Dengvaxia after Sanofi said it must be strictly limited due to evidence it can worsen the disease in people not previously exposed to the infection. Nearly 734,000 children aged 9 and over in the Philippines have received one dose of the vaccine as part of a program that cost 3.5 billion pesos ($69.54 million).
Note: This US government webpage states, "Since 1988, over 18,897 petitions have been filed with the VICP [Vaccine Injury Compensation Program]. Over that 29-year time period, 16,857 petitions have been adjudicated, with 5,782 of those determined to be compensable. Total compensation paid over the life of the program is approximately $3.7 billion." Why aren't these large numbers being reported in the media? For more along these lines, see concise summaries of deeply revealing vaccine controversy news articles from reliable major media sources.
Regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken. The digital pill combines two existing products: the former blockbuster psychiatric medication Abilify - long used to treat schizophrenia and bipolar disorder - with a sensor tracking system first approved in 2012. Experts say the technology could be a useful tool, but it will also change how doctors relate to their patients as theyre able to see whether they are following instructions. The pill has not yet been shown to actually improve patients medication compliance, a feature insurers are likely to insist on before paying for the pill. Additionally, patients must be willing to allow their doctors and caregivers to access the digital information. The technology carries risks for patient privacy, too, if there are breaches of medical data or unauthorized use as a surveillance tool, said James Giordano, a professor of neurology at Georgetown University Medical Center. Could this type of device be used for real-time surveillance? The answer is of course it could, said Giordano. The new pill, Abilify MyCite, is embedded with a digital sensor that is activated by stomach fluids, sending a signal to a patch worn by the patient and notifying a digital smartphone app that the medication has been taken.
Note: In 2010, it was quietly reported that Novartis AG would be seeking regulatory approval for such "chip-in-a-pill technology". For more along these lines, see concise summaries of deeply revealing news articles on microchip implants and the disappearance of privacy.
The nations leading heart experts on Monday issued new guidelines for high blood pressure that mean tens of millions more Americans will meet the criteria for the condition. Under the guidelines ... the number of men under age 45 with a diagnosis of high blood pressure will triple, and the prevalence among women under age 45 will double. The number of adults with high blood pressure, or hypertension, will rise to 103 million from 72 million under the previous standard. The number of people who are new candidates for drug treatment will rise ... by an estimated 4.2 million people. To reach the goals others may have to take more drugs or increase the dosages. The change is due largely to convincing data from a federal study published in 2015. That study, called Sprint, explored whether markedly lower blood pressure in older people - lower than researchers had ever tried to establish - might be both achievable and beneficial. In participants who were assigned to get their systolic pressures below 120, the incidence of heart attacks, heart failure and strokes fell by a third, and the risk of death fell by nearly a quarter. But more intensive drug treatment in so many more patients may increase rates of kidney disease. In the Sprint trial, the incidence of acute kidney injury was twice as high in the group receiving drugs to reduce their systolic pressure to 120. Lifestyle changes like diet and exercise can help many patients lower blood pressure. But many of the newly diagnosed are likely to wind up on drugs.
Note: The effect of this huge change is that billions more dollars will now flow into Big Pharma as millions of consumers are led to believe their blood pressure is dangerously high. Are drugs the best answer? For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical industry corruption and health.
President Donald Trump on Monday announced he is nominating Alex Azar, a former pharmaceutical company executive and George W. Bush administration official, to succeed Tom Price as the secretary of the Department of Health and Human Services. He previously served as HHS general counsel and deputy secretary for President George W. Bush. Following his time with the administration, he worked for pharmaceutical giant Eli Lilly & Co. [He] became president of Lilly USA in 2012. As part of his role at Lilly USA, Azar was on the board of directors for the Boards of the Biotechnology Industry Organization (BIO), a drug lobbying group. In an October letter, Reps. Raul Grijalva, D-Arizona, Mark Pocan, D-Wisconsin, and Jan Schakowsky, D-Illinois, wrote that under his leadership, Azar's company fought "against federal and state legislation to increase drug pricing transparency." And a lawsuit filed in Massachusetts in early 2017 alleges that the company shot up prices on insulin "in near lock step" with two other pharmaceutical manufacturers. Following Yale Law School, Azar clerked for Supreme Court Justice Antonin Scalia, and later joined the Whitewater independent counsel headed by his "mentor" Ken Starr.
Note: Rather than draining the swamp, Trump continues to deepen the swamp in his administration. Besides this most recent appointment, he has installed Goldman Sachs executives as his Treasury secretary, top economic adviser, deputy national security adviser and chief strategist. Even his top Wall Street regulator is a former attorney for Goldman. For more, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry.
Federal agents arrested the founder of a major drug company in an early-morning raid Thursday on charges stemming from an alleged scheme to get doctors to illegally prescribe a powerful opioid to patients who don't need it. John Kapoor ... is the billionaire founder and former CEO of the pharmaceutical company Insys Therapeutics. He faces charges including racketeering, conspiracy, bribery and fraud. Kapoor is the most significant pharmaceutical executive to be criminally charged in response to the nationwide opioid crisis. Kapoor stepped down as CEO of Insys in January but still serves on its board. The company makes a spray version of fentanyl, a highly addictive opioid intended only for cancer patients. Authorities allege Insys marketed the drug as part of a scheme to get non-cancer doctors to prescribe it. Numerous physicians were allegedly paid bribes by the company to push the painkilling drug. Insys made 18,000 payments to doctors in 2016 that totaled more than $2 million. Headache doctors, back pain specialists and even a psychiatrist ... received thousands of dollars to promote the drug last year. Last December, six other Insys executives were indicted on federal charges in Boston in connection with the alleged scheme to bribe doctors to unnecessarily prescribe the painkilling drug.
Note: For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical industry corruption and health.
Trumps nominee for drug czar, the US congressman Tom Marino, was forced to withdraw after a report by the Washington Post and CBSs 60 Minutes highlighted his role in forging legislation that hinders the DEAs ability to move against drug distributors or pharmacies recklessly dispensing the opioid painkillers at the heart of the epidemic, which claims more than 100 lives a day. Marinos acceptance of substantial donations from those same companies compromised his nomination to head the federal agency charged with tackling the opioid crisis. But for Congress, the process was nothing unusual. Hundreds of millions of dollars flow to lobbyists and politicians on Capitol Hill each year to shape laws and policies that keep drug company profits growing. The impact of so much drug company money coursing through the veins of Congress is often incremental or largely unseen by the American public. But on occasion it has a hugely visible impact. While lobbying shapes medical policy across the board, it has had a profound impact on the opioid epidemic as deaths quadrupled between 1999 and 2015. The pharmaceutical industry poured resources into attempting to place blame for the crisis on the millions who have became addicted instead of on the mass prescribing of powerful opioids. Some of the pressure came through industry-funded groups such as the Pain Care Forum, which spent $740m over a decade lobbying in Washington and state legislatures against limits on opioid prescribing.
Note: This excellent article has lots more on the intense level of corruption found in this opioid crisis. For more, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry.
In the midst of the worst drug epidemic in American history, the U.S. Drug Enforcement Administration's ability to keep addictive opioids off U.S. streets was derailed - that according to Joe Rannazzisi, one of the most important whistleblowers ever interviewed by 60 Minutes. Rannazzisi ran the DEA's Office of Diversion Control, the division that regulates and investigates the pharmaceutical industry. He says the opioid crisis was allowed to spread - aided by Congress, lobbyists, and a drug distribution industry that shipped, almost unchecked, hundreds of millions of pills to rogue pharmacies and pain clinics providing the rocket fuel for a crisis that, over the last two decades, has claimed 200,000 lives. His greatest ire is reserved for the ... middlemen that ship the pain pills from manufacturers, like Purdue Pharma and Johnson & Johnson to drug stores all over the country. Rannazzisi accuses the distributors of fueling the opioid epidemic. "This is an industry that allowed millions and millions of drugs to go into bad pharmacies and doctors' offices, that distributed them out to people who had no legitimate need for those drugs," [said Rannazzisi]. In 2013, Joe Rannazzisi and his DEA investigators were trying to crack down. Then ... with the help of members of Congress, the drug industry began to quietly pave the way for legislation that essentially would strip the DEA of its ... ability to immediately freeze suspicious shipments of prescription narcotics to keep drugs off U.S. streets.
Note: See also this informative Washington Post article for more information on this sad topic. Lots more available here. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in pharmaceutical industry.
In April 2016, at the height of the deadliest drug epidemic in U.S. history, Congress effectively stripped the Drug Enforcement Administration of its most potent weapon against large drug companies suspected of spilling prescription narcotics onto the nations streets. By then, the opioid war had claimed 200,000 lives. Overdose deaths continue to rise. A handful of members of Congress, allied with the nations major drug distributors, prevailed upon the DEA and the Justice Department to agree to a more industry-friendly law. The new law makes it virtually impossible for the DEA to freeze suspicious narcotic shipments from the companies, according to internal agency and Justice Department documents and an independent assessment. Political action committees representing the industry contributed at least $1.5 million to the 23 lawmakers who sponsored or co-sponsored four versions of the bill. The drug industry, the manufacturers, wholesalers, distributors and chain drugstores, have an influence over Congress that has never been seen before, said Joseph T. Rannazzisi, who ran the DEAs division responsible for regulating the drug industry and led a decade-long campaign of aggressive enforcement until he was forced out of the agency in 2015. I mean, to get Congress to pass a bill to protect their interests in the height of an opioid epidemic just shows me how much influence they have. The DEA and Justice Department have denied or delayed more than a dozen requests filed by The Post and 60 Minutes under the Freedom of Information Act for public records that might shed additional light on the matter.
Note: The city of Everett, Washington is currently suing Purdue Pharma, maker of the opioid pain medication OxyContin, for the company's alleged role in the diversion of its pills to black market buyers. For other reliable information on pharmaceutical involvement in the huge increase in opioid deaths, see Dr. Mercola's excellent article. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in pharmaceutical industry.
A puzzling study of U.S. pregnancies found that women who had miscarriages between 2010 and 2012 were more likely to have had back-to-back annual flu shots that included protection against swine flu. Past studies have found flu vaccines are safe during pregnancy, though theres been little research on impact of flu vaccinations given in the first three months of pregnancy. This study focused only on miscarriages, which occur in the first 19 weeks of pregnancy and are common. The studys authors, two of whom are CDC researchers, saw a big difference when they looked at women who had miscarried within 28 days of getting a shot that included protection against swine flu, but it was only when the women also had had a flu shot the previous season. They found 17 of 485 miscarriages they studied involved women whose vaccinations followed that pattern. Just four of a comparable 485 healthy pregnancies involved women who were vaccinated that way. Some of the same researchers are working on a larger study looking at more recent data to see if a possible link between swine flu vaccine and miscarriage holds up.
Note: Shortly after publication, this article was removed from the ABC News website. The complete article text is available here. The study in Vaccine can be found on this page. An important article on this study by Robert F. Kennedy, Jr. on this webpage further states "in women who received the H1N1 vaccine in the previous flu season, the odds of spontaneous abortion in the 28 days after receiving a flu vaccine was 7.7 times greater." Could it be that the major media don't want to lose the huge revenue gained by drug ads by pharmaceuticals?
Why do Americans continue to pay the highest prices for medicine in the world? Lawmakers have sculpted specific policies, often not found in many other nations, that boost pharmaceutical industry profits. Meanwhile, the drug industry has spent $61 million on state elections and nearly $67 million on federal elections since 2010. Both parties have made pivotal decisions ... that have kept drug prices high. Insurance companies and pharmacy benefit managers, or PBMs, across the U.S., face at least nine class-action lawsuits alleging they attached arbitrary premiums to the prices of often less-expensive, generic prescription drugs. The plaintiffs also accuse the PBMs and insurers of imposing so-called gag clauses on pharmacies to keep pharmacists from telling consumers that they could save money by paying out of pocket. The system could be denying customers $120 billion in discounts and rebates. Should drugs developed at taxpayer expense be sold to Americans at sky high prices? In the past, the federal government passed a rule saying no but that rule was rescinded in 1995. If Americans were allowed to import lower-priced drugs from places like Canada, it would save government agencies alone $6 billion. But ... Americans are still prohibited from engaging in such importation. The federal government could [also] save billions of dollars a year by having Medicare use its huge market power to negotiate - or require - lower drug prices for the program's beneficiaries.
Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma profiteering and health.
About one out of every 12 U.S. doctors gets money, lunch or something else of value from companies that make opioid drugs, researchers reported Wednesday. Companies are spending much more time and effort marketing opioids to doctors than they are other, less addictive painkillers, the researchers found. They say their findings help explain why doctors have played such an important role in the opioid overuse epidemic. A large proportion of physicians received payments - one in 12 physicians overall, said Dr. Scott Hadland of the Boston Medical Center. Tens of millions of dollars were transferred for marketing purposes for opioids. In some cases they are money provided directly to physicians - for example, the speaking fees, the consultant fees and the honoraria. In other cases it is reimbursement for things like travel, Hadland said. Between 2013 and 2015, the team found 375,266 payments worth $46 million made to more than 68,000 doctors. The top 1 percent of physicians (681 of them) received 82.5 percent of total payments in dollars, the team wrote in their report. A study published last year found that physicians who accepted even one meal sponsored by a drug company were much more likely to prescribe a name-brand drug to patients later. The Centers for Disease Control and Prevention says doctors are definitely helping drive the addiction crisis. The result is deadly. More than 30,000 Americans died from opioid overdoses in 2015.
Note: The city of Everett, Washington is currently suing Purdue Pharma, maker of the opioid pain medication OxyContin, for the company's alleged role in the diversion of its pills to black market buyers. For other reliable information on pharmaceutical involvement in the huge increase in opioid deaths, see Dr. Mercola's excellent article. For more along these lines, see concise summaries of deeply revealing pharmaceutical corruption news articles from reliable major media sources.
Martin Shkreli - famously known as the guy that jacked up the price of a lifesaving AIDS treatment by 5,000% - finally saw his day in court, albeit for a completely unrelated case involving an unrelated company. The trial ... found Shkreli guilty of three counts of fraud for essentially lying to his investors about how he would invest their money and when they would be paid back. The conviction, carrying a potential 20 years in prison, is no joke. Yet the notorious self-promoter took the opportunity to ... let the world know he wasnt fazed. And why should he be? How Shkreli got rich in the first place remains not just legal but celebrated. The real crime of the Pharma Bro is the unrepentant greed that drives him, as well as the industry hes thrived in. Sen. Bernie Sanders has attempted to put a stop to this greed with recently introduced legislation to cap prices for pharmaceuticals developed by government-funded research. Far from a new idea, Sanders has been pushing for a bill like this for decades. While raising the price of a life-saving drug by 5,000% rightfully drew the scorn of millions of people, price gouging is all too common for the industry. Take the EpiPen, the lifesaving device for kids and adults with severe allergies, whose price was famously hiked up over 500% ... after it was acquired by Mylan. Laws that protect investors in these companies are what landed Shkreli in court. Yet until there are laws to protect patients from drug company extortion, like the one proposed by Sanders, the line of Pharma Bros ready to take his place is already queued up.
Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma profiteering and corporate corruption.
Since 2000, the number of overdose deaths from drugs in the U.S. has risen more than 137%. Deaths from opioids - which include painkillers and heroin - make up a large portion of these deaths; 91 Americans die every day from an opioid overdose. Federal numbers like these reveal a dire situation. But a new study finds that many opioid-related deaths are underreported, and that the full picture of the epidemic may be worse than even those numbers show. In the report, Christopher Ruhm, a professor of public policy & economics at the University of Virginia ... found that nationwide, the death rate from opioids is 24% higher than what has been estimated previously. Deaths related to heroin, which is cheaper than prescription painkillers, are 22% higher, he says. When hospitals enter the cause of death on a persons death certificate, the drugs that contributed might not be specified, or multiple drugs will be listed as present. Between 20%-25% of the overdose death certificates Ruhm studied did not have any drug specified, suggesting that statewide estimates of deaths linked to opioids could be significantly off. Ruhm found that the overall death rates from opioids were substantially underreported across the U.S. - by more than half in Pennsylvania, for example. The growth in death rates from 2008 to 2014 - the time period Ruhm studied - was also substantially underestimated in many states.
Note: The city of Everett, Washington is currently suing Purdue Pharma, maker of the opioid pain medication OxyContin, for the company's alleged role in the diversion of its pills to black market buyers. For other reliable information on pharmaceutical involvement in the huge increase in opioid deaths, see Dr. Mercola's excellent article. For more along these lines, see concise summaries of deeply revealing pharmaceutical corruption news articles from reliable major media sources.
Americans take more pills today than at any other time in recent history - and far more than people in any other country. Much of that medication use is lifesaving or at least life-improving. But a lot is not. The amount of harm stemming from inappropriate prescription medication is staggering. Almost 1.3 million people went to U.S. emergency rooms due to adverse drug effects in 2014, and about 124,000 died from those events. Thats according to estimates based on data from the Centers for Disease Control and Prevention and the Food and Drug Administration. Other research suggests that up to half of those events were preventable. All of that bad medicine is costly, too. An estimated $200 billion per year is spent in the U.S. on the unnecessary and improper use of medication, for the drugs themselves and related medical costs. Our previous surveys have found that higher drug costs - including more expensive drugs and higher out-of-pocket costs - also strain household budgets, with many people telling us they had to cut back on groceries or delay paying other bills to pay for their prescriptions. Total spending on drug ads targeting consumers reached $6.4 billion last year, 64 percent more than in 2012. Thats $1.3 billion more than the FDAs entire 2017 budget. Drug companies spend even more - $24 billion in 2012 alone - on marketing just to doctors through ads in medical journals, face-to-face sales, free medication samples, and educational and promotional meetings.
Note: For more, see this informative article . For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma profiteering and health.
Allowing Americans to purchase lower-priced medicines from other countries would save the federal government alone more than $6 billion, according to a new analysis from the Congressional Budget Office. Under existing law, drugmakers are permitted to produce pharmaceuticals abroad and then import them into the United States, where ... they charge Americans the highest prices for medicines in the world. However, while drugmakers themselves are allowed to import medicines, current law prohibits U.S. consumers and pharmaceutical wholesalers from doing so, even when the same medicines are sold at much lower prices abroad. Spending millions on campaign donations and lobbying, the pharmaceutical industry has for years successfully fought off legislation to end the prohibition. This year nearly 17 years after President Bill Clintons administration killed ... drug importation legislation the importation initiative has once again been renewed. Looking to take advantage of President Donald Trumps promise to lower drug prices, Vermont Sen. Bernie Sanders ... introduced the Affordable and Safe Prescription Drug Importation Act on Feb. 28. Overall, campaign spending by the pharmaceutical industry is skyrocketing. Congressional donations from pharmaceutical PACs are up 11 percent as compared with a similar time frame in 2015, and donations to ranking members of health-related committees have risen by 80 percent from two years ago. Lobbying is also on the rise, according to a Kaiser Health News analysis.
Note: For more along these lines, see concise summaries of deeply revealing news articles on government corruption and Big Pharma profiteering.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
